Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 EULAR Congress
• Data suggest efficacy over standard of care for the treatment of psoriatic arthritis • Izokibep was well-tolerated, having a safety profile consistent with previous studies and the IL-17A inhibitor therapeutic class • Supports hypothesis that izokibep offers greater efficacy with high potency and small size, as well as strategy of evaluating IL-17A inhibition’s potential for transformative efficacy across many disease states Solna, Sweden, Los Angeles, USA, and Shanghai, China, June 3, 2022 – ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals today announced data from a